Clinicopathologic features of TP53-mutated myeloid disease with blasts of 10% to less than 20%
| Characteristic . | M/A or MDS-TP53 by ICC and WHO (n = 8) . | M/A-TP53 by ICC only (n = 8) . | P value . |
|---|---|---|---|
| Age at dx (y), median (range) | 64.1 (51.4-74) | 67.5 (38.5-77.1) | NS |
| Sex, male, n (%) | 6 (75) | 4 (50) | NS |
| CBC at dx, median (range) | |||
| ANC, ×103/μL | 1.0 (0.4-1.5) | 1.2 (0.3-1.9) | NS |
| Hb, g/dL | 8.7 (6.8-12.3) | 8.4 (6.6-11.3) | NS |
| Plt, ×103/μL | 56 (22-114) | 41 (10-88) | NS |
| BM blast %, median (range) | 15 (11-17.5) | 15 (10-17.5) | NS |
| CK, n (%) | 8 (100) | 8 (100) | NS |
| MK, n (%) | 7 (100) | 7 (100) | NS |
| TP53 VAF, median (range) | 48.5 (21-89) | 42.3 (19-48.3) | NS |
| 0 additional mutations, n (%) | 7 (88) | 7 (88) | NS |
| HMA therapy, n (%) | 6 (75) | 6 (75) | NS |
| SCT, n (%) | 0 (0) | 2 (25) | NS |
| Characteristic . | M/A or MDS-TP53 by ICC and WHO (n = 8) . | M/A-TP53 by ICC only (n = 8) . | P value . |
|---|---|---|---|
| Age at dx (y), median (range) | 64.1 (51.4-74) | 67.5 (38.5-77.1) | NS |
| Sex, male, n (%) | 6 (75) | 4 (50) | NS |
| CBC at dx, median (range) | |||
| ANC, ×103/μL | 1.0 (0.4-1.5) | 1.2 (0.3-1.9) | NS |
| Hb, g/dL | 8.7 (6.8-12.3) | 8.4 (6.6-11.3) | NS |
| Plt, ×103/μL | 56 (22-114) | 41 (10-88) | NS |
| BM blast %, median (range) | 15 (11-17.5) | 15 (10-17.5) | NS |
| CK, n (%) | 8 (100) | 8 (100) | NS |
| MK, n (%) | 7 (100) | 7 (100) | NS |
| TP53 VAF, median (range) | 48.5 (21-89) | 42.3 (19-48.3) | NS |
| 0 additional mutations, n (%) | 7 (88) | 7 (88) | NS |
| HMA therapy, n (%) | 6 (75) | 6 (75) | NS |
| SCT, n (%) | 0 (0) | 2 (25) | NS |
Abbreviations are explained in Tables 1 and 2.
M/A, MDS/AML; SCT, stem cell transplant.